BIOTECH Patent News - Patent Expiries of Key Therapies Cut Chronic Heart Failure Market in Half by 2016.
Decision Resources (Waltham, MA), one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of key therapies, most notably GlaxoSmithKline’s Coreg and Roche’s Dilatrend/Kredex, will cause the chronic heart failure drug market to decline by more than 50%, from $2.5 billion in 2006 to $1.2 billion in 2016.
Related Results
Food and Drug Administration
Hatchepsut: The Female Pharaoh
Carvedilol: Test your drug IQ
SMITHKLINE BEECHAM: New research reaffirms benefits of beta-blockade in heart…
WHEN DID SOLOMON DIE?
The new Pharmacor report entitled Chronic Heart Failure finds that although the market to treat the disease has a wide array of effective and well-established treatments, many patients remain under-treated as a …
Read the rest of this article with a Free Trial at HighBeam Research.
